# First GSDIa gene therapy wins FDA approval

> The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit.

_Source: FDA announcement, cross-checked with Reuters · 2026-08-20 · 5 min read · Verified against primary sources_

Canonical: https://iyu.app/e/fda-genglycos-first-gsdia-therapy

## The 60-second version

The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit.

**Key points**

- Genglycos is the first approved GSDIa treatment.
- A 48-week study found a 31% mean reduction in daily cornstarch intake versus placebo.
- Accelerated approval leaves long-term benefit and safety questions to follow-up studies.

**Verdict.** This is a meaningful new option, not the end of specialist care.

## Full explainer


### What changed — First GSDIa gene therapy wins FDA approval

The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit.


### Why it matters — Genglycos is the first approved GSDIa treatment.

The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit. Genglycos is the first approved GSDIa treatment. This is a meaningful new option, not the end of specialist care.


### Why it matters — A 48-week study found a 31% mean reduction in daily cornstarch intake versus placebo.

The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit. A 48-week study found a 31% mean reduction in daily cornstarch intake versus placebo. This is a meaningful new option, not the end of specialist care.


### Why it matters — Accelerated approval leaves long-term benefit and safety questions to follow-up studies.

The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit. Accelerated approval leaves long-term benefit and safety questions to follow-up studies. This is a meaningful new option, not the end of specialist care.

> This is a meaningful new option, not the end of specialist care.


## Primary sources

- [U.S. FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia)
- [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/ultragenyx-gene-therapy-wins-first-fda-approval-rare-metabolic-disorder-2026-08-19/)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._